During Google I/O 2025 on Tuesday, Google took the wraps off Gemma 3n, a model designed to run “smoothly” on phones, laptops, and tablets. Available in preview starting Tuesday, Gemma 3n can ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Emilio Parra Doiztua / Bloomberg / Getty Images Pfizer said late Monday that it has agreed to a deal to help develop and market a Chinese cancer drug across the globe. Chinese firm 3SBio is ...

The deal underscores solid demand for Chinese assets from global pharmaceutical firms looking to replenish their drug pipelines and boost their presence in the China market, even as the trade war ...

“At the moment, there is very little risk” for originators that are “evergreening” their products — the practice of making minor adjustments to a drug in order to secure new patents.

Generics and biosimilars are significantly cheaper than branded medications, which usually drives down the cost across the board for that drug market. When pharmaceutical companies do not face ...

Many women have, for decades, taken a drug called phenazopyridine to control pain from urinary tract infections. Sold under such brand names as Azo and Uristat, it’s available in most US ...

The Huawei MateBook Fold Ultimate Design takes the form of an 18-inch tablet, with a thickness of just 7.3 millimetres when unfolded. Weighing 1.16kg, the device folds down to 13 inches ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.

The country's Justice Minister Gérald Darmanin announced the €400-million scheme during a visit to French Guiana on Sunday. France plans to build a high-security prison in the Amazon as part of ...

After Donald Trump signed an executive order slashing drug prices last week, experts have highlighted how pharmacy benefit managers (PBMs) could be hit the hardest despite pharmaceutical companies ...